Image of GA progression
Image of GA progression
Icon of a clock

77% of patients said the disease impacted their vision faster than they expected13*

Icon of two people - One orange and one white

In only 2 years, ~50% of patients with GA lose 2 lines of vision10†

Icon of an eye

Don't delay. Your patients' vision will never be better than it is today.

Your guidance. Their moments.

A partnership that could preserve more vision for longer

Photo of Jan, GA patient

It is important for patients to have conversations with their doctor. I have so much more hope since starting treatment.”

– Jan, GA patient

Photo of Dr. Esther Kim

My patients tell me they feel empowered that they're doing something to slow the progression of GA.”7

– Dr. Esther Kim

Patients want to be proactive about their GA

Icon of a pie chart with 84%

In a survey of people with self-reported GA,

84% of them said they would try a new treatment to slow GA in hopes of preserving their vision for longer13*

Time lost is vision lost, but there's something you can do

*Results from a telephone survey of 203 individuals with self-reported GA. Participants were compensated for their time and the survey was sponsored by a pharmaceutical company.

†Retrospective analysis of the Chroma, Spectri, and Proxima A trials, including 2006 study eyes from patients with bilateral GA.

GA=geographic atrophy.

See efficacy data

Next page
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.